Literature DB >> 3989322

Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin.

S J Stolz, J P Davis, J M Vergeront, B A Crass, P J Chesney, P J Wand, M S Bergdoll.   

Abstract

The presence of Staphylococcus aureus producing toxic shock toxin (TST) and the absence of antibody to TST (anti-TST) in acute-phase sera are markers for toxic shock syndrome (TSS). We used radioimmunoassay methods to examine 133 acute-phase and 277 convalescent-phase serum specimens from 181 patients with TSS for anti-TST. Among confirmed menstrual cases, nine (9.5%) of 95 patients had demonstrable anti-TST in acute-phase sera obtained during the first seven days of illness; patients with probable or non-menstrual TSS had a higher prevalence of anti-TST in acute-phase sera. Five (33.3%) of 15 individuals with confirmed menstrual TSS developed anti-TST as early as seven to nine days after TSS onset; 32 (62.7%) of 51 patients had demonstrable anti-TST in sera obtained more than one year after their episode of TSS. This study demonstrates a gradual rate and low magnitude of development of anti-TST after TSS and supports the diagnostic usefulness of measuring anti-TST levels in sera from patients suspected of having TSS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3989322     DOI: 10.1093/infdis/151.5.883

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.

Authors:  Per Akesson; Linnea Moritz; Mikael Truedsson; Bertil Christensson; Ulrich von Pawel-Rammingen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Determination by western blot (immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1 and enterotoxin A, B, or C during infection with TSS- and non-TSS-associated Staphylococcus aureus.

Authors:  J L Whiting; P M Rosten; A W Chow
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

5.  [IgM antibodies to toxic shock syndrome toxin-1 in human sera and human immunoglobulins].

Authors:  N Dickgiesser; F Düzgün
Journal:  Klin Wochenschr       Date:  1988-01-04

6.  Persistent bactericidal defect in neutrophils from a young woman who recovered from toxic shock syndrome.

Authors:  E M Berger; C J Beehler; J E Repine
Journal:  Inflammation       Date:  1986-12       Impact factor: 4.092

7.  Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

Authors:  R D LeClaire; S Bavari
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

8.  Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1.

Authors:  B Christensson; P J Johansson; V A Oxelius
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

9.  [IgG antibodies to toxic shock syndrome toxin-1 (TSST-1) in human sera].

Authors:  N Dickgiesser; B Kustermann
Journal:  Klin Wochenschr       Date:  1987-03-16

Review 10.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.